Why the study?
Several new drugs have become available to treat influenza, but little information remains available regarding their efficacy and safety in special populations.
What are the efficacy and safety profiles of currently available antiviral treatments for influenza?
What are the efficacy and safety profiles of currently available antiviral treatments for influenza?
This review highlights the efficacy and safety of current influenza antivirals while noting the lack of data in special populations and the concerning emergence of resistant viral strains.
Answers are grounded in this paper and cite their sources.
Limited data in critically ill and chronic respiratory patients warrant caution; leaves open need for targeted efficacy and resistance trials.
Influenza is an acute respiratory illness caused by the influenza A, B, and C viruses. It can occur in local outbreaks or seasonal epidemics, with possibility to spread worldwide in a pandemic when a novel strain with significant antigenic differences emerges. During the past years, several new drugs have become available, with different accessibility related to specific countries' approval. We have conducted a review of literature, analyzing the most recent data on efficacy and safety of drugs currently available to treat influenza, with a particular attention toward special populations. Efficacy and safety profile of neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, peramivir) and recently approved cap-dependent endonuclease inhibitor baloxavir marboxil are reported in literature, but still little information is available about special populations such as critically ill patients and patients with a history of chronic respiratory disease. Moreover, the emergence of strains with reduced or no susceptibility to current drugs is a matter of concern, suggesting the need of constant monitoring of viral variants.
No takes yet. Share an insight, caveat, or question.
Palomba et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: